Puma Biotechnology Q4 2025 Revenue Rises 28% Puma reported Q4 revenue $168.9m (+28% YoY) and FY2025 sales $610.4m; management set 2026 guidance of $700–$750m (Investing.com, Mar 28, 2026).

Puma Biotechnology Q4 2025 Revenue Rises 28%: Puma reported Q4 revenue $168.9m (+28% YoY) and FY2025 sales $610.4m; management set 2026 guidance of $700–$750m (Investing.com, Mar 28, 2026). 👈 Read full analysis #PumaBiotechnology #Revenue #FinancialReports #Q4Results #Earnings

Puma Biotechnology: Nerlynx Revenue Up 15% Q4 2025 Puma Biotechnology reported Nerlynx revenue rose 15% sequentially in Q4 2025 (slides published Mar 28, 2026); investors should seek corroboration in Q1/Q2 filings.

Puma Biotechnology: Nerlynx Revenue Up 15% Q4 2025: Puma Biotechnology reported Nerlynx revenue rose 15% sequentially in Q4 2025 (slides published Mar 28, 2026); investors should seek corroboration in Q1/Q2… 👈 Read full analysis #PumaBiotechnology #Nerlynx #Q42025 #Pharmaceuticals #BiotechInvesting